# PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS

> **NCT06391905** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** PCSK9 inhibitor in combination with standard advanced first-line regimen group
- **DRUG:** standard advanced first-line regimen group

## Key facts

- **NCT ID:** NCT06391905
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2028-04-06
- **Final completion:** 2028-05-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391905, "PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06391905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*